TLSI TriSalus Life Sciences, Inc.

NASDAQ
$4.34

TriSalus Life Sciences, Inc. (TLSI) is expected to report earnings on November 16, 2026, after the market close. The consensus earnings estimate is a loss of $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.2% since its last earnings release on August 6, 2026.

TriSalus Life Sciences Reported Earnings, Reaffirms Above Estimates
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.14)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.10

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutic delivery to solid tumors.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.